<p style="margin: 0px 0px 10.66px;">A recent meta-analysis shows a superior risk-benefit profile for NOACs over vitamin K antagonists in patients with Afib and early-stage CKD.</p>

A recent meta-analysis shows a superior risk-benefit profile for NOACs over vitamin K antagonists in patients with Afib and early-stage CKD.

<p>A recent meta-analysis shows a superior risk-benefit profile for NOACs over vitamin K antagonists in patients with Afib and early-stage CKD.</p>

Univadis Practice Changers: NOACs vs VKAs in Afib with early-stage CKD

If you're a family medicine physician or other primary care clinician, you know how hard it is to keep up with the latest research. The Univadis Practice Changers podcast provides expert analysis on the most essential new evidence in medicine. In 5 minutes or less, you'll hear experts go beyond the details of the latest study to the real-world clinical applications. Univadis Practice Changers is a quick look at essential evidence changing your daily practice.

Share Univadis Practice Changers: NOACs vs VKAs in Afib with early-stage CKD

Sign up to save your podcasts

Univadis Practice Changers: NOACs vs VKAs in Afib with early-stage CKD

Univadis Practice Changers: NOACs vs VKAs in Afib with early-stage CKD